DE60022687D1 - Verwendung von steroid-alkaloidderivaten zur umkehrung multipler medikamentenresistenz - Google Patents

Verwendung von steroid-alkaloidderivaten zur umkehrung multipler medikamentenresistenz

Info

Publication number
DE60022687D1
DE60022687D1 DE60022687T DE60022687T DE60022687D1 DE 60022687 D1 DE60022687 D1 DE 60022687D1 DE 60022687 T DE60022687 T DE 60022687T DE 60022687 T DE60022687 T DE 60022687T DE 60022687 D1 DE60022687 D1 DE 60022687D1
Authority
DE
Germany
Prior art keywords
reversal
alkaloid derivatives
steroid alkaloid
multiple medication
families
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60022687T
Other languages
English (en)
Other versions
DE60022687T2 (de
Inventor
Mordechai Liscovitch
Yaakov Lavie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE60022687D1 publication Critical patent/DE60022687D1/de
Publication of DE60022687T2 publication Critical patent/DE60022687T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60022687T 1999-12-30 2000-12-28 Verwendung von steroid-alkaloidderivaten zur umkehrung multipler medikamentenresistenz Expired - Fee Related DE60022687T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13380999 1999-12-30
IL13380999A IL133809A0 (en) 1999-12-30 1999-12-30 Steroidal alkaloids and pharmaceutical compositions comprising them
PCT/IL2000/000866 WO2001049279A2 (en) 1999-12-30 2000-12-28 Use of steroidal alkaloids to reverse multidrug resistance

Publications (2)

Publication Number Publication Date
DE60022687D1 true DE60022687D1 (de) 2005-10-20
DE60022687T2 DE60022687T2 (de) 2006-07-06

Family

ID=11073663

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022687T Expired - Fee Related DE60022687T2 (de) 1999-12-30 2000-12-28 Verwendung von steroid-alkaloidderivaten zur umkehrung multipler medikamentenresistenz

Country Status (9)

Country Link
US (1) US20030114393A1 (de)
EP (1) EP1274445B1 (de)
JP (1) JP2003519178A (de)
AT (1) ATE304360T1 (de)
AU (1) AU2022901A (de)
CA (1) CA2395642A1 (de)
DE (1) DE60022687T2 (de)
IL (2) IL133809A0 (de)
WO (1) WO2001049279A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
US20070281040A1 (en) * 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2129677B1 (de) 2007-03-07 2014-12-17 Infinity Discovery, Inc. Heterocyclische cyclopamin-analoga und verfahren zu ihrer verwendung
MX2009009429A (es) 2007-03-07 2010-07-05 Infinity Discovery Inc Analogos de ciclopamina lactama y metodos de uso de los mismos.
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP2224807B1 (de) * 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Verfahren für stereoselektive reduktion
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
MX2012005163A (es) * 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
EP2571357B1 (de) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemische verbindungen, zusammensetzungen und verfahren zur kinasemodulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9457033B2 (en) 2011-02-15 2016-10-04 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
JP6001060B2 (ja) * 2011-06-06 2016-10-05 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RS58023B2 (sr) 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
AU2013352256A1 (en) 2012-11-29 2015-06-18 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103043635B (zh) * 2012-12-25 2015-04-22 浙江大学 一种抗耐药性的顺铂矿化液及其制备方法和应用
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
CN104224815A (zh) * 2013-06-18 2014-12-24 复旦大学 澳洲茄胺在制备抗肿瘤药物中的应用
FR3008699B1 (fr) * 2013-07-19 2015-08-21 Univ Picardie Nouveaux composes derives de la solanidine
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2970997C (en) 2013-12-23 2023-01-03 Eric Marsault Atp synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN105911176A (zh) * 2016-04-15 2016-08-31 广西壮族自治区梧州食品药品检验所 一种浙贝母中贝母素甲、贝母素乙的测定方法
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN108853120B (zh) * 2018-07-23 2021-02-19 华南农业大学 贝母辛在制备抗白色念珠菌药物中的应用
CN110613720B (zh) * 2019-09-24 2022-06-03 华南农业大学 蒜藜芦碱用于制备防治白色念珠菌感染的药物中的应用
CN112138066B (zh) * 2020-09-09 2022-02-25 中南大学湘雅医院 龙葵或龙葵提取物在增加抗生素或抗肿瘤药物敏感性中的应用
CN112121059B (zh) * 2020-09-28 2022-02-11 郑州大学第一附属医院 一种中药单体组合物及用于治疗食管癌的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5005588A (en) * 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
SE9600229D0 (sv) * 1996-01-23 1996-01-23 Pharmacia Ab Novel potentiating agents
AU7980098A (en) * 1997-06-20 1999-01-04 Elena Y. Enioutina Method to enhance innate immunity defense mechanisms by treatment with plan t-derived alkaloids
US6616925B1 (en) * 1998-04-02 2003-09-09 I.D.M. Immuno-Designed Molecules Combined preparation for the treatment of neoplasic diseases or of infectious diseases
AU768130B2 (en) * 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto

Also Published As

Publication number Publication date
DE60022687T2 (de) 2006-07-06
JP2003519178A (ja) 2003-06-17
IL149913A (en) 2006-08-01
ATE304360T1 (de) 2005-09-15
US20030114393A1 (en) 2003-06-19
AU2022901A (en) 2001-07-16
WO2001049279A3 (en) 2002-10-17
EP1274445B1 (de) 2005-09-14
EP1274445A2 (de) 2003-01-15
CA2395642A1 (en) 2001-07-12
WO2001049279A2 (en) 2001-07-12
IL133809A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
DE60022687D1 (de) Verwendung von steroid-alkaloidderivaten zur umkehrung multipler medikamentenresistenz
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
BRPI0412798A (pt) uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
WO2006028525A3 (en) [3.2.0] heterocyclic compounds and methods of using the same
MX2007006063A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
AP2070A (en) Quinolinone derivatives
TW200621238A (en) Pharmaceutical formulation
DE602004025698D1 (de) PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
Zloh et al. Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
WO2005105094A3 (en) Cancer treatment method
Lin et al. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
BRPI0313763B8 (pt) imidazóis 2,4,5-trissubstituídos, seus usos, e composições farmacêutica e anti-microbiana
ATE424808T1 (de) Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
UA97629C2 (ru) Фармацевтическая композиция, имеющая противоопухолевую активность, и способы
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee